Challenges and opportunities in biotechnology.
The biotechnology industry is thriving, and many predicted accomplishments have actually occurred during the last decade. Cloning and expression of genetic information is now simple and routine. Initial commercial products have been realized, but there is much yet to be accomplished in evaluating the clinical significance of many other gene products made available by biotechnology resources. During the next decade, human health care and the pharmaceutical industry should be affected substantially by first- and second-generation recombinant DNA products. Recombinant vaccines, blood coagulation factors, and known biological modulators produced by rDNA technologies should be widely used. Further opportunities will be realized with increasing discoveries of new bioactive molecules and identification of NANB hepatitis and AIDS infectious agents. Full exploitation of health care products will depend on innovative new delivery systems or the ability to reconstruct mammalian and plant genes, providing for in-situ delivery of the necessary gene products.
Overby
L R
LR
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D003001:Cloning, Molecular; D004274:DNA, Recombinant; D004345:Drug Industry; D005169:Factor VIII / Q000138:chemical synthesis / Q000627:therapeutic use; D005818:Genetic Engineering / Q000379:methods; D017325:Hepatitis B Vaccines; D006526:Hepatitis C / Q000517:prevention & control; D006801:Humans; D013677:Medical Laboratory Science; D010960:Plasminogen Activators / Q000138:chemical synthesis / Q000627:therapeutic use; D011499:Protein Processing, Post-Translational; D012190:Retroviridae / Q000276:immunology; D018139:Simplexvirus / Q000276:immunology; D014761:Viral Hepatitis Vaccines / Q000138:chemical synthesis / Q000627:therapeutic use; D014765:Viral Vaccines / Q000138:chemical synthesis / Q000145:classification / Q000627:therapeutic use
D004274:DNA, Recombinant; D017325:Hepatitis B Vaccines; D014761:Viral Hepatitis Vaccines; D014765:Viral Vaccines; D005169:Factor VIII; D010960:Plasminogen Activators